Orphan drugs expenditure in the Netherlands in the period 2006-2012.
about
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countriesPharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.Impact of orphan drugs on Latvian budget.Negotiating prices of drugs for rare diseases.Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.Budget impact analysis of medicines: updated systematic review and implications.
P2860
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
@ast
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
@en
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
@nl
type
label
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
@ast
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
@en
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
@nl
prefLabel
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
@ast
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
@en
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
@nl
P2860
P1476
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
@en
P2093
Adri Steenhoek
Leona Hakkaart
P2860
P2888
P356
10.1186/S13023-014-0154-0
P577
2014-10-11T00:00:00Z
P5875
P6179
1005037034